Neuren Pharmaceuticals Limited
Status: Publicly traded
Direct answer
Neuren Pharmaceuticals Limited is publicly traded on ASX under the ticker NEU.AX.
Neuren Pharmaceuticals Limited, an Australian biopharmaceutical firm, is dedicated to developing innovative treatments for neurological conditions. Its leading drug candidate, trofinetide, is currently in advanced (Phase III) clinical trials for Rett syndrome, following its successful completion of Phase II trials for Fragile X syndrome. The company is also progressing with NNZ-2591, which has finished its initial...
Can you invest in Neuren Pharmaceuticals Limited?
Yes. Neuren Pharmaceuticals Limited trades publicly on ASX as NEU.AX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Neuren Pharmaceuticals Limited
Detailed equity research is provided by MarketSnap.